ELSE NUTRN HLDG BABYF
- Market cap
- —
- P/E
- 0.0×
Follow BABYF
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | 2.19 | 3.29 | 7.90 | 3.02 | 1.16 | 0.07 | 0.07 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | 4.60 | 40.00 | 35.30 | 14.30 | 8.33 | 2.64 | 0.80 |
High Price
|
|||
| — | — | — | — | 28 | 28 | 35 | — | 13 | 13 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 0 | 1 | 4 | 7 | 7 | 6 | 4 |
Revenue
|
|||
| — | — | — | 100.00% | 33.61% | 15.85% | 15.37% | (0.91%) | (14.57%) | 5.31% |
Gross Margin
|
|||
| — | — | — | 0 | (18) | (1) | (14) | (12) | (11) | (6) |
EBT
|
|||
| — | — | — | 100.00% | (1,626.47%) | (34.52%) | (206.57%) | (166.75%) | (190.42%) | (147.39%) |
EBT Margin
|
|||
| — | — | — | 0 | (18) | (1) | (14) | (12) | (11) | (6) |
Net Income
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| — | — | — | 0.83 | 1.36 | 3.84 | 6.03 | 5.94 | 3.47 | 1.26 |
Revenue/Sh
|
|||
| — | — | — | (8.00) | (22.00) | (1.32) | (12.00) | (10.00) | (7.00) | (1.90) |
Earnings/Sh
|
|||
| — | — | — | 0.00 | (8.80) | (12.91) | (14.80) | (11.62) | (3.94) | (0.67) |
Cash Flow/Sh
|
|||
| — | — | — | 0.00 | (0.21) | (0.23) | (0.11) | 0.00 | (0.03) | 0.01 |
Capex/Sh
|
|||
| — | — | — | 0.00 | (9.01) | (13.14) | (14.91) | (11.62) | (3.97) | (0.66) |
Free CF/Sh
|
|||
| — | — | — | 0.00 | 10.28 | 21.92 | 11.04 | 4.26 | 0.76 | (0.85) |
Book Value/Sh
|
|||
| — | — | — | 1 | 1 | 1 | 1 | 1 | 2 | 3 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 0.00 | 22.79 | 2.35 | 0.67 | 0.29 | 0.03 | 0.06 |
PS Ratio
|
|||
| — | — | — | 0.00 | 3.04 | 0.41 | 0.36 | 0.40 | 0.16 | 0.00 |
PB Ratio
|
|||
| — | — | — | 0.00 | 5.87 | (2.96) | (0.91) | (0.04) | 0.07 | 0.35 |
EV/Sales
|
|||
| — | — | — | 0.00 | 0.00 | 0.87 | 0.37 | 0.02 | (0.06) | (0.66) |
EV/FCF
|
|||
| — | — | — | — | (7) | (13) | (16) | (14) | (7) | (2) |
Op' Cash Flow
|
|||
| — | — | — | — | 0 | 0 | 0 | — | 0 | 0 |
Capex
|
|||
| — | — | — | — | (7) | (13) | (16) | (14) | (7) | (2) |
FCF
|
|||
| — | — | — | — | 20 | 22 | 16 | 9 | 1 | (3) |
Working Cap'
|
|||
| — | — | — | — | 0 | 0 | 2 | 2 | 0 | 1 |
Total Debt
|
|||
| — | — | — | — | (19) | (20) | (10) | (2) | 0 | 1 |
Net Debt
|
|||
| — | — | — | — | 8 | 21 | 12 | 5 | 1 | (3) |
Sh' Equity
|
|||
| — | — | — | 0.00% | (164.43%) | (5.36%) | (58.41%) | (72.21%) | (127.20%) | (163.97%) |
ROA
|
|||
| — | — | — | 0.00% | 0.00% | (584.40%) | (593.89%) | (288.13%) | (451.10%) | 0.00% |
ROIC
|
|||
| — | — | — | 0.00% | 0.00% | (8.69%) | (81.23%) | (136.24%) | (354.00%) | 776.75% |
ROE
|
|||
ELSE NUTRN HLDG (BABYF) Latest News
29 Jun
Else Nutrition receives conditional approval from the Canadian Securities Exchange. CSE conditional approval may improve trading access and market visibility for the company.
1 Jun
Else Nutrition Holdings initiates manufacturing expansion in Q2 2026. Manufacturing drive launch supports scaled production capacity from 2026 onward.
Else Nutrition launches manufacturing drive in Q2 2026. Manufacturing drive starting 2026 may moderately boost production capacity and operations.
Else Nutrition starts manufacturing drive in Q2 2026. Manufacturing drive planned for 2026 may moderately expand production capacity and operations.
15 May
Else Nutrition reported Q1 2026 results with significantly improved gross margins and reduced net loss. Quarterly earnings showing margin gains and lower losses can lift near-term investor sentiment around financial performance.
Else Nutrition reported first quarter 2026 results with significant gross margin improvement and reduced net loss. Improved margins and lower losses in quarterly results indicate better operational efficiency likely to support modest stock and sentiment gains.
15 Apr
Else Nutrition endorses the Trump administration's FY2027 plan to strengthen infant formula regulations. Expanded infant formula regulations may improve Else Nutrition's competitive position through higher compliance standards.
Else Nutrition commends Trump administration's expanded efforts to strengthen infant formula regulations in FY2027. Regulatory tightening in infant formulas could moderately shift market dynamics and favor compliant producers like Else Nutrition.
31 Mar
Else Nutrition reports fiscal year 2025 financial results, highlighting operational progress, strengthened financial foundation, and clear path toward profitability. Financial results and profitability outlook can significantly alter investor sentiment and company trajectory.
10 Mar
Else Nutrition stands to benefit from FDA regulatory progress on infant formula protein standards. FDA progress on infant formula protein standards directly boosts Else Nutrition's product positioning and market access.
29 Jan
Else Nutrition surpasses one million cans sold since launch. One million cans sold marks a sales milestone for Else Nutrition.
7 Jan
Else Nutrition plans Canadian market relaunch in 2026. Canadian relaunch in 2026 signals moderate expansion potential that could lift revenue and sentiment over time.
17 Dec
Else Nutrition achieves transformative operational and financial progress in 2025. Transformative operational and financial progress signals substantial positive effects on company trajectory.
2 Dec
Else Nutrition renewed its five-year tender with Israel's largest health fund for baby feeding solutions. Five-year renewal with Israel's largest health fund secures major revenue stream and strengthens market position for Else Nutrition.
18 Nov
President Trump signs FDA funding package including congressional directive to streamline regulatory pathway for non-dairy, non-soy plant-based infant formula, marking a breakthrough for Else Nutrition (BABYD). Streamlined FDA pathway for plant-based infant formula accelerates Else Nutrition product approvals and market expansion.
Else Nutrition announces President Trump signed FDA funding package with congressional directive streamlining regulatory pathway for non-dairy non-soy plant-based infant formula. Streamlined FDA pathway for plant-based infant formula directly speeds Else Nutrition product approvals and market entry.
14 Nov
Else Nutrition achieved significant operational turnaround in Q3 2025 via gross margin expansion and cost reductions. Q3 2025 margin gains and cost cuts signal better efficiency but remain incremental for long-term trajectory.